Syncona leads CHF35 million A round for Anaveon

Anaveon AG (Zurich, Switzerland) closed the first undisclosed tranche of a CHF35 million ($35 million) series A round Tuesday to help bring its biologic IL-2 receptor agonists into the clinic. Syncona Ltd. (LSE:SYNC) is leading the round with a CHF28 million ($28 million) commitment. Novartis Venture Fund is also participating.

The company spun out of the University of Zurich in 2017 with seed funding from UZH Life Sciences Fund and BaseLaunch accelerator...